BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062-5067. [PMID: 19770374 DOI: 10.1200/jco.2009.22.2083] [Cited by in Crossref: 593] [Cited by in F6Publishing: 288] [Article Influence: 45.6] [Reference Citation Analysis]
Number Citing Articles
1 Zhao Z, Wang P, Gao Y, He J. The high expression instead of mutation of p53 is predictive of overall survival in patients with esophageal squamous-cell carcinoma: a meta-analysis. Cancer Med 2017;6:54-66. [PMID: 27882726 DOI: 10.1002/cam4.945] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
2 Michalarea V, Smyth EC. Neoadjuvant DCF vs. ACF for resectable oesophageal squamous cell carcinoma. J Thorac Dis 2017;9:2868-70. [PMID: 29221258 DOI: 10.21037/jtd.2017.08.148] [Reference Citation Analysis]
3 Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014;8:142-149. [PMID: 24210755 DOI: 10.1016/j.molonc.2013.10.007] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 7.0] [Reference Citation Analysis]
4 Lee JM, Chen SC, Yang SM, Tseng YF, Yang PW, Huang PM. Comparison of single- and multi-incision minimally invasive esophagectomy (MIE) for treating esophageal cancer: a propensity-matched study. Surg Endosc 2017;31:2925-31. [PMID: 27826778 DOI: 10.1007/s00464-016-5308-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Franco P, Arcadipane F, Strignano P, Spadi R, Trino E, Martini S, Iorio GC, Satolli MA, Airoldi M, Romagnoli R, Camandona M, Ricardi U. Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials. Med Oncol 2017;34:40. [PMID: 28176241 DOI: 10.1007/s12032-017-0898-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Bundred JR, Hollis AC, Evans R, Hodson J, Whiting JL, Griffiths EA. Impact of postoperative complications on survival after oesophagectomy for oesophageal cancer. BJS Open 2020;4:405-15. [PMID: 32064788 DOI: 10.1002/bjs5.50264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Bhattacharyya T, Arunsingh M, Chakraborty S, Harilal V, Sasidharan R, Saha S, Thambudorai R, Roy B, Banerjee S, Roy P, Ray S, Mallick I. Can the CROSS protocol be safely implemented in real world scenario with broader eligibility criteria? Experience from a tertiary care centre in India. Ecancermedicalscience 2021;15:1291. [PMID: 34824614 DOI: 10.3332/ecancer.2021.1291] [Reference Citation Analysis]
8 Chmelo J, Phillips AW, Greystoke A, Charman SJ, Avery L, Hallsworth K, Welford J, Sinclair RCF. A feasibility study to investigate the utility of a home-based exercise intervention during and after neo-adjuvant chemotherapy for oesophago-gastric cancer-the ChemoFit study protocol. Pilot Feasibility Stud 2020;6:50. [PMID: 32346484 DOI: 10.1186/s40814-020-00597-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Zhou GZ, Wu QQ. Role of preoperative chemoradiotherapy in the comprehensive treatment of esophageal cancer. Shijie Huaren Xiaohua Zazhi 2012; 20(17): 1526-1530 [DOI: 10.11569/wcjd.v20.i17.1526] [Reference Citation Analysis]
10 Siddique MZ, Mehmood S, Ismail M, Yasmeen A, Asad-Ur-Rehman, Abu Bakar M, Khattak S, Syed AA, Yusuf MA. Pre-operative percutaneous endoscopic gastrostomy tube placement does not increase post-operative complications or mortality in oesophageal cancer. J Gastrointest Oncol 2019;10:492-8. [PMID: 31183199 DOI: 10.21037/jgo.2019.03.08] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wang F, Duan H, Cai M, Fu J, Ma G, Yang H, Tan Z, Hu R, Lin P, Zhang X. Prognostic significance of the pN classification supplemented by body mass index for esophageal squamous cell carcinoma. Thorac Cancer 2015;6:765-71. [PMID: 26557916 DOI: 10.1111/1759-7714.12259] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
12 Li XK, Fan QX. Progress in medication treatment of esophageal cancer. Shijie Huaren Xiaohua Zazhi 2012; 20(35): 3482-3487 [DOI: 10.11569/wcjd.v20.i35.3482] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
13 Brescia AA, Broderick SR, Crabtree TD, Puri V, Musick JF, Bell JM, Kreisel D, Krupnick AS, Patterson GA, Meyers BF. Adjuvant Therapy for Positive Nodes After Induction Therapy and Resection of Esophageal Cancer. Ann Thorac Surg 2016;101:200-8; discussion 208-10. [PMID: 26507424 DOI: 10.1016/j.athoracsur.2015.09.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
14 Knight WRC, Zylstra J, Van Hemelrijck M, Griffin N, Jacques AET, Maisey N, Baker CR, Gossage JA, Largergren J, Davies AR. Patterns of recurrence in oesophageal cancer following oesophagectomy in the era of neoadjuvant chemotherapy. BJS Open 2017;1:182-90. [PMID: 29951621 DOI: 10.1002/bjs5.30] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
15 Raman V, Jawitz OK, Voigt SL, Yang CJ, D'Amico TA, Harpole DH Jr. The Role of Adjuvant Therapy in Patients With Margin-Positive (R1) Esophagectomy: A National Analysis. J Surg Res 2020;249:82-90. [PMID: 31926400 DOI: 10.1016/j.jss.2019.11.035] [Reference Citation Analysis]
16 Zhang W, Li Y, Xue L, Qu D, Jiang Z, Wang Z, Yang Z, Zhou A. Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study. Cancer Manag Res 2021;13:2163-70. [PMID: 33688259 DOI: 10.2147/CMAR.S298360] [Reference Citation Analysis]
17 Yoon HH, Lewis MA, Foster NR, Sukov WR, Khan M, Sattler CA, Wiktor AE, Wu TT, Jenkins RB, Sinicrope FA. Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma. Int J Cancer 2016;139:1626-31. [PMID: 27198655 DOI: 10.1002/ijc.30200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
18 Rubenstein JH, Shaheen NJ. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology. 2015;149:302-17.e1. [PMID: 25957861 DOI: 10.1053/j.gastro.2015.04.053] [Cited by in Crossref: 182] [Cited by in F6Publishing: 175] [Article Influence: 26.0] [Reference Citation Analysis]
19 Yang PW, Chiang TH, Hsieh CY, Huang YC, Wong LF, Hung MC, Tsai JC, Lee JM. The effect of ephrin-A1 on resistance to Photofrin-mediated photodynamic therapy in esophageal squamous cell carcinoma cells. Lasers Med Sci 2015;30:2353-61. [PMID: 26450615 DOI: 10.1007/s10103-015-1812-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
20 Zhu CM, Ling YH, Xi SY, Luo RZ, Chen JW, Yun JP, Xie D, Cai MY. Prognostic significance of the pN classification supplemented by vascular invasion for esophageal squamous cell carcinoma. PLoS One 2014;9:e96129. [PMID: 24763284 DOI: 10.1371/journal.pone.0096129] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
21 Lim SH, Shim YM, Park SH, Kim HK, Choi YS, Ahn MJ, Park K, Zo JI, Sun JM. A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma. Cancer Res Treat 2017;49:816-23. [PMID: 27857024 DOI: 10.4143/crt.2016.417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 Zhang Y, Liu Z, Liang Y, Chen E, Zhang H, Gao Z, Wang J. The effectiveness and prognostic factors of radioactive iodine-125 seed implantation for the treatment of cervical lymph node recurrence of esophageal squamous cell carcinoma after external beam radiation therapy. J Contemp Brachytherapy 2020;12:579-85. [PMID: 33437306 DOI: 10.5114/jcb.2020.101691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Koyanagi K, Kanamori K, Ninomiya Y, Yatabe K, Higuchi T, Yamamoto M, Tajima K, Ozawa S. Progress in Multimodal Treatment for Advanced Esophageal Squamous Cell Carcinoma: Results of Multi-Institutional Trials Conducted in Japan. Cancers (Basel) 2020;13:E51. [PMID: 33375499 DOI: 10.3390/cancers13010051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist. 2011;16:844-858. [PMID: 21632459 DOI: 10.1634/theoncologist.2010-0387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
25 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 2011;71:541-555. [PMID: 21443280 DOI: 10.2165/11585460-000000000-000003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Liu T, Ding S, Dang J, Wang H, Chen J, Li G. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis. Radiat Oncol 2019;14:176. [PMID: 31619265 DOI: 10.1186/s13014-019-1388-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
27 Hiyoshi Y, Yoshida N, Watanabe M, Kurashige J, Baba Y, Sakamoto Y, Baba H. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. World J Surg 2017;41:480-6. [PMID: 27637603 DOI: 10.1007/s00268-016-3649-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
28 Park JS, Van der Wall H, Kennedy C, Falk GL. Oesophageal adenocarcinoma: In the era of extended lymphadenectomy, is the value of neoadjuvant therapy being attenuated? World J Gastrointest Surg 2021; 13(10): 1235-1244 [PMID: 34754391 DOI: 10.4240/wjgs.v13.i10.1235] [Reference Citation Analysis]
29 Lin MW, Yang PW, Lee JM. Translational research in thoracic surgery-the National Taiwan University Hospital experience. J Thorac Dis 2016;8:S642-7. [PMID: 27651941 DOI: 10.21037/jtd.2016.07.95] [Reference Citation Analysis]
30 NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383:1561-1571. [PMID: 24576776 DOI: 10.1016/s0140-6736(13)62159-5] [Cited by in Crossref: 256] [Cited by in F6Publishing: 160] [Article Influence: 32.0] [Reference Citation Analysis]
31 Shridhar R, Imani-Shikhabadi R, Davis B, Streeter OA, Thomas CR Jr. Curative treatment of esophageal cancer; an evidenced based review. J Gastrointest Cancer 2013;44:375-84. [PMID: 23824628 DOI: 10.1007/s12029-013-9511-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
32 Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, Tanaka Y, Hamamoto Y, Matsushita H, Nagase M, Hosoya Y. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci. 2013;104:1455-1460. [PMID: 23991649 DOI: 10.1111/cas.12274] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 11.2] [Reference Citation Analysis]
33 Khan O, Goh S, Byrne B, Somers S, Mercer S, Toh S. Long-term outcomes of extended proximal gastrectomy for oesophagogastric junctional tumours. World J Surg. 2011;35:2245-2251. [PMID: 21850599 DOI: 10.1007/s00268-011-1235-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
34 Allen S, Brown V, Prabhu P, Scott M, Rockall T, Preston S, Sultan J. A randomised controlled trial to assess whether prehabilitation improves fitness in patients undergoing neoadjuvant treatment prior to oesophagogastric cancer surgery: study protocol. BMJ Open 2018;8:e023190. [PMID: 30580268 DOI: 10.1136/bmjopen-2018-023190] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
35 Li S, Liu H, Diao C, Wang X, Gao M, Li Z, Song L, Gao X, Han J, Wang F, Li W, Han X. Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis. Oncotarget 2017;8:36339-53. [PMID: 28423740 DOI: 10.18632/oncotarget.16193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
36 Soror T, Kho G, Zhao KL, Ismail M, Badakhshi H. Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer. J Thorac Dis 2018;10:4069-76. [PMID: 30174850 DOI: 10.21037/jtd.2018.06.85] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
37 Zeng Y, Yu W, Liu Q, Yu WW, Zhu ZF, Zhao WX, Liu J, Wang JM, Fu XL, Liu Y, Cai XW. Difference in failure patterns of pT3-4N0-3M0 esophageal cancer treated by surgery vs surgery plus radiotherapy. World J Gastrointest Oncol 2019; 11(12): 1172-1181 [PMID: 31908722 DOI: 10.4251/wjgo.v11.i12.1172] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Zhao ZF, Li JX, Ye R, Wu X, Gao LL, Niu BL. Interleukin-6 as a potential molecular target in esophageal squamous cell carcinoma. Oncol Lett 2016;11:925-32. [PMID: 26893670 DOI: 10.3892/ol.2015.3990] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
39 Yuan M, Bao Y, Ma Z, Men Y, Wang Y, Hui Z. The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients. Front Oncol 2021;11:628706. [PMID: 33777777 DOI: 10.3389/fonc.2021.628706] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Chen WK, Chen CA, Chi CW, Li LH, Lin CP, Shieh HR, Hsu ML, Ko CC, Hwang JJ, Chen YJ. Moscatilin Inhibits Growth of Human Esophageal Cancer Xenograft and Sensitizes Cancer Cells to Radiotherapy. J Clin Med 2019;8:E187. [PMID: 30764514 DOI: 10.3390/jcm8020187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
41 Chen Y, Wu X, Hao D, Cheng X, Zhang L, Zhang Y, Ke S, Shi W, He C. Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma. Oncotarget 2019;10:4069-78. [PMID: 31258850 DOI: 10.18632/oncotarget.23861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Reeh M, Ghadban T, Uzunoglu FG, Nentwich MF, Bockhorn M, Pantel K, Izbicki JR, Vashist YK. Hamburg-Glasgow classification: preoperative staging by combination of disseminated tumour load and systemic inflammation in oesophageal carcinoma. Br J Cancer 2017;117:612-8. [PMID: 28704837 DOI: 10.1038/bjc.2017.219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
43 Reid TD, Chan DS, Roberts SA, Crosby TD, Williams GT, Lewis WG. Prognostic significance of circumferential resection margin involvement following oesophagectomy for cancer and the predictive role of endoluminal ultrasonography. Br J Cancer 2012;107:1925-31. [PMID: 23169281 DOI: 10.1038/bjc.2012.511] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
44 Liu J, Yue J, Xing L, Yu J. Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer. Front Med. 2013;7:172-179. [PMID: 23681891 DOI: 10.1007/s11684-013-0268-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
45 Deng X, He W, Jiang Y, Deng S, Mao T, Leng X, Luo Q, Zheng K, Han Y. The impact of adjuvant therapy on survival for node-negative esophageal squamous cell carcinoma: a propensity score-matched analysis. Ann Transl Med 2021;9:998. [PMID: 34277798 DOI: 10.21037/atm-21-2539] [Reference Citation Analysis]
46 Han S, Wang Y, Ge C, Gao M, Wang X, Wang F, Sun L, Li S, Dong T, Dang Z, Cui W, Zhang G, Liu N. Pharmaceutical inhibition of AXL suppresses tumor growth and invasion of esophageal squamous cell carcinoma. Exp Ther Med 2020;20:41. [PMID: 32952632 DOI: 10.3892/etm.2020.9169] [Reference Citation Analysis]
47 Kim IH. Current status of adjuvant chemotherapy for gastric cancer. World J Gastrointest Oncol 2019; 11(9): 679-685 [PMID: 31558973 DOI: 10.4251/wjgo.v11.i9.679] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
48 Saeki H, Sohda M, Sakai M, Sano A, Shirabe K. Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinoma. Ann Gastroenterol Surg 2020;4:490-7. [PMID: 33005843 DOI: 10.1002/ags3.12364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
49 Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2013;24:2844-9. [PMID: 23975663 DOI: 10.1093/annonc/mdt339] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
50 Turgeman I, Ben-Aharon I. Evolving treatment paradigms in esophageal cancer. Ann Transl Med 2021;9:903. [PMID: 34164537 DOI: 10.21037/atm.2020.03.110] [Reference Citation Analysis]
51 Schweigert M, Dubecz A, Stein HJ. Oesophageal cancer--an overview. Nat Rev Gastroenterol Hepatol. 2013;10:230-244. [PMID: 23296250 DOI: 10.1038/nrgastro.2012.236] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
52 Jung HK, Tae CH, Lee HA, Lee H, Don Choi K, Park JC, Kwon JG, Choi YJ, Hong SJ, Sung J, Chung WC, Kim KB, Kim SY, Song KH, Park KS, Jeon SW, Kim BW, Ryu HS, Lee OJ, Baik GH, Kim YS, Jung HY; Korean College of Helicobacter and Upper Gastrointestinal Research. Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6,354 Korean patients. PLoS One 2020;15:e0231456. [PMID: 32275699 DOI: 10.1371/journal.pone.0231456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
53 Kosumi K, Baba Y, Ishimoto T, Harada K, Nakamura K, Ohuchi M, Kiyozumi Y, Izumi D, Tokunaga R, Taki K, Higashi T, Miyata T, Kurashige J, Hiyoshi Y, Iwagami S, Sakamoto Y, Miyamoto Y, Yoshida N, Watanabe M, Baba H. Neutrophil/lymphocyte ratio predicts the prognosis in esophageal squamous cell carcinoma patients. Surg Today 2016;46:405-13. [PMID: 26036223 DOI: 10.1007/s00595-015-1197-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
54 Selby P, Kaplan R, Cameron D, Cooper M, Seymour M. The Royal College of Physicians Simms Lecture, 6 December 2011: clinical research networks and the benefits of intensive healthcare systems. Clin Med (Lond) 2012;12:446-52. [PMID: 23101146 DOI: 10.7861/clinmedicine.12-5-446] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
55 Bunting DM, Lai WW, Berrisford RG, Wheatley TJ, Drake B, Sanders G. Positron emission tomography-computed tomography in oesophageal cancer staging: a tailored approach. World J Surg 2015;39:1000-7. [PMID: 25446482 DOI: 10.1007/s00268-014-2892-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
56 Sisic L, Blank S, Weichert W, Jäger D, Springfeld C, Hochreiter M, Büchler M, Ott K. Prognostic impact of lymph node involvement and the extent of lymphadenectomy (LAD) in adenocarcinoma of the esophagogastric junction (AEG). Langenbecks Arch Surg 2013;398:973-81. [PMID: 23887283 DOI: 10.1007/s00423-013-1101-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
57 Mukherjee S, Hurt CN, Gwynne S, Bateman A, Gollins S, Radhakrishna G, Hawkins M, Canham J, Lewis W, Grabsch HI, Sharma RA, Wade W, Maggs R, Tranter B, Roberts A, Sebag-Montefiore D, Maughan T, Griffiths G, Crosby T. NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Cancer 2015;15:48. [PMID: 25880814 DOI: 10.1186/s12885-015-1062-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
58 Gosavi R, Chia C, Michael M, Heriot AG, Warrier SK, Kong JC. Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis. Int J Colorectal Dis 2021;36:2063-70. [PMID: 33945007 DOI: 10.1007/s00384-021-03945-3] [Reference Citation Analysis]
59 Powell AGMT, Karran A, Blake P, Christian A, Roberts SA, Lewis WG. Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy. BJS Open 2020;4:593-600. [PMID: 32374504 DOI: 10.1002/bjs5.50287] [Reference Citation Analysis]
60 Hegemann NS, Koepple R, Walter F, Boeckle D, Fendler WP, Angele MK, Boeck S, Belka C, Roeder F. Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival. Strahlenther Onkol 2018;194:435-43. [PMID: 29349603 DOI: 10.1007/s00066-018-1261-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 van Rossum PSN, Fried DV, Zhang L, Hofstetter WL, Ho L, Meijer GJ, Carter BW, Court LE, Lin SH. The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma. Eur J Nucl Med Mol Imaging 2017;44:71-80. [PMID: 27511188 DOI: 10.1007/s00259-016-3478-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
62 Spitzner M, Emons G, Schütz KB, Wolff HA, Rieken S, Ghadimi BM, Schneider G, Grade M. Inhibition of Wnt/β-Catenin Signaling Sensitizes Esophageal Cancer Cells to Chemoradiotherapy. Int J Mol Sci 2021;22:10301. [PMID: 34638639 DOI: 10.3390/ijms221910301] [Reference Citation Analysis]
63 Knight WRC, Baker CR, Griffin N, Wulaningsih W, Kelly M, Davies AR, Gossage JA; Guy’s & St Thomas’ Oesophago-Gastric Research Group. Does a high Mandard score really define a poor response to chemotherapy in oesophageal adenocarcinoma? Br J Cancer 2021;124:1653-60. [PMID: 33742143 DOI: 10.1038/s41416-021-01290-4] [Reference Citation Analysis]
64 Shen LY, Wang H, Dong B, Yan WP, Lin Y, Shi Q, Chen KN. Possible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling. Oncotarget 2016;7:4531-41. [PMID: 26673820 DOI: 10.18632/oncotarget.6554] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
65 Kountourakis P, Correa AM, Hofstetter WL, Lee JH, Bhutani MS, Rice DC, Komaki R, Maru DM, Ross WA, Vaporciyan A, Swisher SG, Ajani JA. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer 2011;117:925-30. [PMID: 20960497 DOI: 10.1002/cncr.25651] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
66 Deng J, Wang C, Xiang M, Liu F, Liu Y, Zhao K. Meta-analysis of postoperative efficacy in patients receiving chemoradiotherapy followed by surgery for resectable esophageal carcinoma. Diagn Pathol. 2014;9:151. [PMID: 25030066 DOI: 10.1186/1746-1596-9-151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
67 Won E, Ilson DH. Management of localized esophageal cancer in the older patient. Oncologist 2014;19:367-74. [PMID: 24664485 DOI: 10.1634/theoncologist.2013-0178] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
68 Manzini G, Klotz U, Henne-Bruns D, Kremer M. Validity of studies suggesting preoperative chemotherapy for resectable thoracic esophageal cancer: A critical appraisal of randomized trials. World J Gastrointest Oncol 2020; 12(1): 113-123 [PMID: 31966919 DOI: 10.4251/wjgo.v12.i1.113] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Coyle C, Cafferty FH, Rowley S, MacKenzie M, Berkman L, Gupta S, Pramesh CS, Gilbert D, Kynaston H, Cameron D. ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp Clin Trials. 2016;51:56-64. [PMID: 27777129 DOI: 10.1016/j.cct.2016.10.004] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 13.2] [Reference Citation Analysis]
70 Guo JC, Xie YM, Ran LQ, Cao HH, Sun C, Wu JY, Wu ZY, Liao LD, Zhao WJ, Fang WK, Li EM, Xu LY, Schachner M, Xie JJ. L1CAM drives oncogenicity in esophageal squamous cell carcinoma by stimulation of ezrin transcription. J Mol Med (Berl) 2017;95:1355-68. [PMID: 28939985 DOI: 10.1007/s00109-017-1595-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
71 Zheng Y, Cao X, Wen J, Yang H, Luo K, Liu Q, Huang Q, Chen J, Fu J. Smoking affects treatment outcome in patients with resected esophageal squamous cell carcinoma who received chemotherapy. PLoS One 2015;10:e0123246. [PMID: 25874561 DOI: 10.1371/journal.pone.0123246] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
72 Guo X, Fang W, Li Z, Yu Z, Rong T, Fu J, Han Y, Tan L, Chen C, Liu S, Liao Y, Xiao G, Wei Y, Zhu C, Li H, Luo J, Xing W. Adjuvant radiotherapy, chemotherapy or surgery alone for high-risk histological node negative esophageal squamous cell carcinoma: Protocol for a multicenter prospective randomized controlled trial. Thorac Cancer 2018;9:1801-6. [PMID: 30276974 DOI: 10.1111/1759-7714.12882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
73 Triantafyllou T, Wijnhoven B. Multidisciplinary treatment of esophageal cancer: The role of active surveillance after neoadjuvant chemoradiation. Ann Gastroenterol Surg 2020;4:352-9. [PMID: 32724878 DOI: 10.1002/ags3.12350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Kauppi J, Räsänen J, Sihvo E, Huuhtanen R, Nelskylä K, Salo J. Open versus minimally invasive esophagectomy: clinical outcomes for locally advanced esophageal adenocarcinoma. Surg Endosc 2015;29:2614-9. [PMID: 25480610 DOI: 10.1007/s00464-014-3978-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
75 Jain VK, Cunningham D, Rao S. Chemotherapy for operable gastric cancer: current perspectives. Indian J Surg Oncol. 2011;2:334-342. [PMID: 23204792 DOI: 10.1007/s13193-012-0139-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
76 Kleinberg L, Brock M, Gibson M. Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus. Curr Treat Options Oncol 2015;16:35. [PMID: 26112428 DOI: 10.1007/s11864-015-0352-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
77 Turkington RC, Knight LA, Blayney JK, Secrier M, Douglas R, Parkes EE, Sutton EK, Stevenson L, McManus D, Halliday S, McCavigan AM, Logan GE, Walker SM, Steele CJ, Perner J, Bornschein J, MacRae S, Miremadi A, McCarron E, McQuaid S, Arthur K, James JA, Eatock MM, O'Neill R, Noble F, Underwood TJ, Harkin DP, Salto-Tellez M, Fitzgerald RC, Kennedy RD; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group. Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. Gut 2019;68:1918-27. [PMID: 30852560 DOI: 10.1136/gutjnl-2018-317624] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
78 Fan N, Wang Z, Zhou C, Bludau M, Contino G, Zhao Y, Bruns C. Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis. EClinicalMedicine 2021;42:101183. [PMID: 34805809 DOI: 10.1016/j.eclinm.2021.101183] [Reference Citation Analysis]
79 Yaremko BP, Palma DA, Erickson AL, Pierce G, Malthaner RA, Inculet RI, Dar AR, Rodrigues GB, Yu E. Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal esophagus and gastro-esophageal junction. Radiat Oncol 2013;8:33. [PMID: 23398690 DOI: 10.1186/1748-717X-8-33] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
80 Zhu K, Xu Y, Fu J, Mohamud FA, Duan Z, Tan S, Zhao Z, Chen P, Zong L. Proximal Gastrectomy versus Total Gastrectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Comprehensive Analysis of Data from the SEER Registry. Dis Markers 2019;2019:9637972. [PMID: 31976023 DOI: 10.1155/2019/9637972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
81 Su Z, Gay LJ, Strange A, Palles C, Band G, Whiteman DC, Lescai F, Langford C, Nanji M, Edkins S. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett’s esophagus. Nat Genet. 2012;44:1131-1136. [PMID: 22961001 DOI: 10.1038/ng.2408] [Cited by in Crossref: 127] [Cited by in F6Publishing: 109] [Article Influence: 12.7] [Reference Citation Analysis]
82 Ajani JA, Swisher SG. Three angels are dancing on the head of the esophageal cancer pin, but shouldn't we not topple one or two? Ann Surg Oncol 2014;21:2815-6. [PMID: 24756809 DOI: 10.1245/s10434-014-3695-5] [Reference Citation Analysis]
83 Sun HB, Xing WQ, Liu XB, Zheng Y, Yang SJ, Wang ZF, Liu SL, Ba YF, Zhang RX, Liu BX, Fan CC, Chen PN, Liang GH, Yu YK, Liu Q, Wang HR, Li HM, Li ZX; written on Henan Cancer Hospital Thoracic Oncology Group (HCHTOG). Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903). BMC Cancer 2020;20:303. [PMID: 32293362 DOI: 10.1186/s12885-020-06824-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
84 van der Wilk BJ, Eyck BM, Lagarde SM, van der Gaast A, Nuyttens JJME, Wijnhoven BPL, van Lanschot JJB. The optimal neoadjuvant treatment of locally advanced esophageal cancer. J Thorac Dis 2019;11:S621-31. [PMID: 31080638 DOI: 10.21037/jtd.2018.11.143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
85 Zheng Y, Li Y, Liu X, Sun H, Wang Z, Zhang R. Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 Years. Medicine (Baltimore) 2015;94:e1102. [PMID: 26166100 DOI: 10.1097/MD.0000000000001102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
86 Griffiths EA, Gregory CJ, Pursnani KG, Ward JB, Stockwell RC. The use of biodegradable (SX-ELLA) oesophageal stents to treat dysphagia due to benign and malignant oesophageal disease. Surg Endosc. 2012;26:2367-2375. [PMID: 22395954 DOI: 10.1007/s00464-012-2192-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
87 Khalafi S, Lockhart AC, Livingstone AS, El-Rifai W. Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet? Cancers (Basel) 2020;12:E3077. [PMID: 33105560 DOI: 10.3390/cancers12113077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Buergy D, Lohr F, Baack T, Siebenlist K, Haneder S, Michaely H, Wenz F, Boda-Heggemann J. Radiotherapy for tumors of the stomach and gastroesophageal junction--a review of its role in multimodal therapy. Radiat Oncol. 2012;7:192. [PMID: 23157945 DOI: 10.1186/1748-717x-7-192] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
89 Qin HD, Liao XY, Chen YB, Huang SY, Xue WQ, Li FF, Ge XS, Liu DQ, Cai Q, Long J, Li XZ, Hu YZ, Zhang SD, Zhang LJ, Lehrman B, Scott AF, Lin D, Zeng YX, Shugart YY, Jia WH. Genomic Characterization of Esophageal Squamous Cell Carcinoma Reveals Critical Genes Underlying Tumorigenesis and Poor Prognosis. Am J Hum Genet. 2016;98:709-727. [PMID: 27058444 DOI: 10.1016/j.ajhg.2016.02.021] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 12.7] [Reference Citation Analysis]
90 Mayanagi S, Irino T, Kawakubo H, Kitagawa Y. Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer. Ann Gastroenterol Surg 2019;3:269-75. [PMID: 31131355 DOI: 10.1002/ags3.12243] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
91 Tejani MA, Burtness BA. Multi-modality therapy for cancer of the esophagus and GE junction. Curr Treat Options Oncol 2012;13:390-402. [PMID: 22592595 DOI: 10.1007/s11864-012-0193-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
92 Zhang L, Li W, Lyu X, Song Y, Mao Y, Wang S, Huang J. Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Chin J Cancer Res 2017;29:149-55. [PMID: 28536494 DOI: 10.21147/j.issn.1000-9604.2017.02.08] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
93 Palmes D, Brüwer M, Bader FG, Betzler M, Becker H, Bruch HP, Büchler M, Buhr H, Ghadimi BM, Hopt UT, Konopke R, Ott K, Post S, Ritz JP, Ronellenfitsch U, Saeger HD, Senninger N; German Advanced Surgical Treatment Study Group. Diagnostic evaluation, surgical technique, and perioperative management after esophagectomy: consensus statement of the German Advanced Surgical Treatment Study Group. Langenbecks Arch Surg 2011;396:857-66. [PMID: 21713594 DOI: 10.1007/s00423-011-0818-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
94 Hsieh MS, Yang PW, Wong LF, Lee JM. The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma. Oncotarget 2016;7:36956-70. [PMID: 27172793 DOI: 10.18632/oncotarget.9231] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
95 Wang J, Zhang YJ. Combination of concept and clinical practice - putting a high premium on neoadjuvant therapy for adenocarcinoma of the esophagogastric junction. Shijie Huaren Xiaohua Zazhi 2016; 24(21): 3223-3231 [DOI: 10.11569/wcjd.v24.i21.3223] [Reference Citation Analysis]
96 Knight WRC, Yip C, Wulaningsih W, Jacques A, Griffin N, Zylstra J, Van Hemelrijck M, Maisey N, Gaya A, Baker CR, Kelly M, Gossage JA, Lagergren J, Landau D, Goh V, Davies AR, Ngan S, Qureshi A, Deere H, Green M, Chang F, Mahadeva U, Gill-Barman B, George S, Dunn J, Zeki S, Meenan J, Hynes O, Tham G, Iezzi C; Guy's and St Thomas' Oesophago‐Gastric Research Group. Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagus. BJS Open 2019;3:767-76. [PMID: 31832583 DOI: 10.1002/bjs5.50211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
97 Watanabe M, Otake R, Kozuki R, Toihata T, Takahashi K, Okamura A, Imamura Y. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today 2020;50:12-20. [PMID: 31535225 DOI: 10.1007/s00595-019-01878-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 13.3] [Reference Citation Analysis]
98 Rahman S, Thomas B, Maynard N, Park MH, Wahedally M, Trudgill N, Crosby T, Cromwell DA, Underwood TJ. Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery. Br J Surg 2021:znab427. [PMID: 34910129 DOI: 10.1093/bjs/znab427] [Reference Citation Analysis]
99 Fan Y, Jiang Y, Zhou X, Chen Q, Huang Z, Xu Y, Gong L, Yu H, Yang H, Liu J, Lei T, Zhao Q, Mao W. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget 2016;7:50624-34. [PMID: 27244882 DOI: 10.18632/oncotarget.9562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
100 Markar SR, Noordman BJ, Mackenzie H, Findlay JM, Boshier PR, Ni M, Steyerberg EW, van der Gaast A, Hulshof MCCM, Maynard N, van Berge Henegouwen MI, Wijnhoven BPL, Reynolds JV, Van Lanschot JJB, Hanna GB. Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study. Ann Oncol 2017;28:519-27. [PMID: 28039180 DOI: 10.1093/annonc/mdw560] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
101 Huang Z, Li S, Yang X, Lu F, Huang M, Zhang S, Xiong Y, Zhang P, Si J, Ma Y, Yang Y. Long-term survival of patients with locally advanced esophageal squamous cell carcinoma receiving esophagectomy following neoadjuvant chemotherapy: a cohort study. Cancer Manag Res 2019;11:1299-308. [PMID: 30799956 DOI: 10.2147/CMAR.S195355] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
102 Izadi F, Sharpe BP, Breininger SP, Secrier M, Gibson J, Walker RC, Rahman S, Devonshire G, Lloyd MA, Walters ZS, Fitzgerald RC, Rose-Zerilli MJJ, Underwood TJ, On Behalf Of Occams. Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma. Cancers (Basel) 2021;13:3394. [PMID: 34298611 DOI: 10.3390/cancers13143394] [Reference Citation Analysis]
103 Semenkovich TR, Subramanian M, Yan Y, Hofstetter WL, Correa AM, Cassivi SD, Inra ML, Stiles BM, Altorki NK, Chang AC, Brescia AA, Darling GE, Allison F, Broderick SR, Etchill EW, Fernandez FG, Chihara RK, Litle VR, Muñoz-Largacha JA, Kozower BD, Puri V, Meyers BF. Adjuvant Therapy for Node-Positive Esophageal Cancer After Induction and Surgery: A Multisite Study. Ann Thorac Surg 2019;108:828-36. [PMID: 31229485 DOI: 10.1016/j.athoracsur.2019.04.099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
104 Kolk A, Jubitz N, Mengele K, Mantwill K, Bissinger O, Schmitt M, Kremer M, Holm PS. Expression of Y-box-binding protein YB-1 allows stratification into long- and short-term survivors of head and neck cancer patients. Br J Cancer 2011;105:1864-73. [PMID: 22095225 DOI: 10.1038/bjc.2011.491] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
105 Kunishige T, Migita K, Matsumoto S, Wakatsuki K, Nakade H, Miyao S, Kuniyasu H, Sho M. Ring box protein-1 is associated with a poor prognosis and tumor progression in esophageal cancer. Oncol Lett 2020;20:2919-27. [PMID: 32782608 DOI: 10.3892/ol.2020.11840] [Reference Citation Analysis]
106 Bibby BA, Reynolds JV, Maher SG. MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma. PLoS One 2015;10:e0134180. [PMID: 26221725 DOI: 10.1371/journal.pone.0134180] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
107 Yang PW, Liu YC, Chang YH, Lin CC, Huang PM, Hua KT, Lee JM, Hsieh MS. Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC). Front Oncol 2019;9:1138. [PMID: 31781483 DOI: 10.3389/fonc.2019.01138] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
108 Zhao Y, Zhao S, Chen Y, Dong X, Peng C, Sun Q, Shan L, Wang Z, Zhao X. Isolation of circulating tumor cells in patients undergoing surgery for esophageal cancer and a specific confirmation method. Oncol Lett 2019;17:3817-25. [PMID: 30881502 DOI: 10.3892/ol.2019.10017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 Bott RK, George G, McEwen R, Zylstra J, Knight WRC, Baker CR, Kelly M, Griffin N, McAddy N, Maisey N, Van Hemelrijck M, Gossage JA, Lagergren J, Davies AR. Predicting response to neoadjuvant chemotherapy in patients with oesophageal adenocarcinoma. Acta Oncol 2021;:1-8. [PMID: 34613874 DOI: 10.1080/0284186X.2021.1986228] [Reference Citation Analysis]
110 den Bakker CM, Smit JK, Bruynzeel AME, van Grieken NCT, Daams F, Derks S, Cuesta MA, Plukker JTM, van der Peet DL. Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessary. J Thorac Dis 2017;9:S843-50. [PMID: 28815082 DOI: 10.21037/jtd.2017.06.123] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
111 Mukherjee S, Hurt C, Radhakrishna G, Gwynne S, Bateman A, Gollins S, Hawkins MA, Canham J, Grabsch HI, Falk S, Sharma RA, Ray R, Roy R, Cox C, Maynard N, Nixon L, Sebag-Montefiore DJ, Maughan T, Griffiths GO, Crosby TDL. Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. Eur J Cancer 2021;153:153-61. [PMID: 34157617 DOI: 10.1016/j.ejca.2021.05.020] [Reference Citation Analysis]
112 Hou S, Pan Z, Hao X, Hang Q, Ding Y. Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer. Cancers (Basel) 2021;13:5162. [PMID: 34680311 DOI: 10.3390/cancers13205162] [Reference Citation Analysis]
113 Samson P, Robinson C, Bradley J, Lockhart AC, Puri V, Broderick S, Kreisel D, Krupnick AS, Patterson GA, Meyers B, Crabtree T. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients. J Thorac Oncol 2016;11:2227-37. [PMID: 27544058 DOI: 10.1016/j.jtho.2016.07.031] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
114 De Silva N, Schulz L, Paterson A, Qain W, Secrier M, Godfrey E, Cheow H, O'Donovan M, Lao-Sirieix P, Jobanputra M, Hochhauser D, Fitzgerald R, Ford H. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. Br J Cancer 2015;113:1305-12. [PMID: 26484410 DOI: 10.1038/bjc.2015.342] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
115 Sugimura K, Yamasaki M, Yasuda T, Yano M, Hirao M, Fujitani K, Kimura Y, Miyata H, Motoori M, Takeno A, Shiraishi O, Makino T, Kii T, Tanaka K, Satoh T, Mori M, Doki Y. Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003). Ann Gastroenterol Surg 2021;5:75-82. [PMID: 33532683 DOI: 10.1002/ags3.12388] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Kumar T, Pai E, Singh R, Francis NJ, Pandey M. Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials. World J Surg Oncol 2020;18:59. [PMID: 32199464 DOI: 10.1186/s12957-020-01830-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
117 Jiang N, Ge XL, Zhang ZY, Liu J, Wang PP, Sun XC, Yang M. Prognostic Factors for Patients with Esophageal Cancer Receiving Definitive Radiotherapy Alone: A Retrospective Analysis. Cancer Manag Res 2021;13:3229-34. [PMID: 33880065 DOI: 10.2147/CMAR.S300672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Hiraki Y, Kimura Y, Imano M, Kato H, Iwama M, Shiraishi O, Yasuda A, Shinkai M, Makino T, Motoori M, Yamasaki M, Miyata H, Satou T, Satoh T, Furukawa H, Yano M, Doki Y, Yasuda T. Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma. Surg Today 2021;51:118-26. [PMID: 32596796 DOI: 10.1007/s00595-020-02059-7] [Reference Citation Analysis]
119 Nakamura K, Yoshida N, Baba Y, Kosumi K, Uchihara T, Kiyozumi Y, Ohuchi M, Ishimoto T, Iwatsuki M, Sakamoto Y, Watanabe M, Baba H. Elevated preoperative neutrophil-to-lymphocytes ratio predicts poor prognosis after esophagectomy in T1 esophageal cancer. Int J Clin Oncol 2017;22:469-75. [PMID: 28097441 DOI: 10.1007/s10147-017-1090-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
120 Tang H, Zheng H, Tan L, Shen Y, Wang H, Lin M, Wang Q. Neoadjuvant chemoradiotherapy followed by minimally invasive esophagectomy: is it a superior approach for locally advanced resectable esophageal squamous cell carcinoma? J Thorac Dis. 2018;10:963-972. [PMID: 29607169 DOI: 10.21037/jtd.2017.12.108] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
121 Kalikawe R, Baba Y, Nomoto D, Okadome K, Miyake K, Eto K, Hiyoshi Y, Nagai Y, Iwatsuki M, Ishimoto T, Iwagami S, Miyamoto Y, Yoshida N, Watanabe M, Baba H. Lysyl oxidase impacts disease outcomes and correlates with global DNA hypomethylation in esophageal cancer. Cancer Sci 2019;110:3727-37. [PMID: 31599475 DOI: 10.1111/cas.14214] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
122 Wang L, Chen J, Chen L, Deng P, Bu Q, Xiang P, Li M, Lu W, Xu Y, Lin H. 1H-NMR based metabonomic profiling of human esophageal cancer tissue. Mol Cancer. 2013;12:25. [PMID: 23556477 DOI: 10.1186/1476-4598-12-25] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
123 Allen SK, Brown V, White D, King D, Hunt J, Wainwright J, Emery A, Hodge E, Kehinde A, Prabhu P, Rockall TA, Preston SR, Sultan J. Multimodal Prehabilitation During Neoadjuvant Therapy Prior to Esophagogastric Cancer Resection: Effect on Cardiopulmonary Exercise Test Performance, Muscle Mass and Quality of Life-A Pilot Randomized Clinical Trial. Ann Surg Oncol 2021. [PMID: 34725764 DOI: 10.1245/s10434-021-11002-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Sun NN, Ge XL, Liu XS, Xu LL. Histogram analysis of DCE-MRI for chemoradiotherapy response evaluation in locally advanced esophageal squamous cell carcinoma. Radiol Med 2020;125:165-76. [PMID: 31605354 DOI: 10.1007/s11547-019-01081-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
125 Li X, Wu Z, Mei Q, Li X, Guo M, Fu X, Han W. Long non-coding RNA HOTAIR, a driver of malignancy, predicts negative prognosis and exhibits oncogenic activity in oesophageal squamous cell carcinoma. Br J Cancer 2013;109:2266-78. [PMID: 24022190 DOI: 10.1038/bjc.2013.548] [Cited by in Crossref: 113] [Cited by in F6Publishing: 121] [Article Influence: 12.6] [Reference Citation Analysis]
126 Knight WRC, Zylstra J, Wulaningsih W, Van Hemelrijck M, Landau D, Maisey N, Gaya A, Baker CR, Gossage JA, Largergren J, Davies AR; Guy's and St Thomas' Oesophago‐Gastric Research Group. Impact of incremental circumferential resection margin distance on overall survival and recurrence in oesophageal adenocarcinoma. BJS Open 2018;2:229-37. [PMID: 30079392 DOI: 10.1002/bjs5.65] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
127 Thuss-Patience P, Vecchione L, Keilholz U. Should cT2 esophageal cancer get neoadjuvant treatment before surgery? J Thorac Dis 2017;9:2819-23. [PMID: 29221247 DOI: 10.21037/jtd.2017.08.143] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
128 Xie K, Liu S, Liu J. Nomogram predicts survival benefit for non- metastatic esophageal cancer patients who underwent preoperative radiotherapy. Cancer Manag Res 2018;10:3657-68. [PMID: 30271214 DOI: 10.2147/CMAR.S165168] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
129 Chen D, Wang W, Mo J, Ren Q, Miao H, Chen Y, Wen Z. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments. BMC Cancer 2021;21:145. [PMID: 33563244 DOI: 10.1186/s12885-021-07867-9] [Reference Citation Analysis]
130 Cox SJ, O'Cathail SM, Coles B, Crosby T, Mukherjee S. Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas. Curr Oncol Rep 2017;19:7. [PMID: 28213876 DOI: 10.1007/s11912-017-0559-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
131 Harada K, Rogers JE, Iwatsuki M, Yamashita K, Baba H, Ajani JA. Recent advances in treating oesophageal cancer. F1000Res 2020;9:F1000 Faculty Rev-1189. [PMID: 33042518 DOI: 10.12688/f1000research.22926.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
132 Allum WH, Smyth EC, Blazeby JM, Grabsch HI, Griffin SM, Rowley S, Cafferty FH, Langley RE, Cunningham D. Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction. Br J Surg 2019;106:1204-15. [PMID: 31268180 DOI: 10.1002/bjs.11184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
133 Harada K, Mizrak Kaya D, Lopez A, Baba H, Ajani JA. Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. Ann Transl Med 2018;6:80. [PMID: 29666803 DOI: 10.21037/atm.2017.10.28] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
134 Fontana E, Smyth EC, Cunningham D. Esophagogastric Adenocarcinoma: Is More Chemotherapy Better? Curr Treat Options Oncol 2016;17:21. [PMID: 27032643 DOI: 10.1007/s11864-016-0395-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
135 Yoshida N, Baba Y, Baba H. Preoperative malnutrition and prognosis after neoadjuvant chemotherapy followed by subsequent esophagectomy. J Thorac Dis 2017;9:3437-9. [PMID: 29268308 DOI: 10.21037/jtd.2017.09.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
136 Jin Z, Chen D, Chen M, Wang C, Zhang B, Zhang J, Zhu C, Shen J. (Neo)adjuvant Chemoradiotherapy is Beneficial to the Long-term Survival of Locally Advanced Esophageal Squamous Cell Carcinoma: A Network Meta-analysis. World J Surg 2021. [PMID: 34482411 DOI: 10.1007/s00268-021-06301-2] [Reference Citation Analysis]
137 Yoon HH, Khan M, Shi Q, Cassivi SD, Wu TT, Quevedo JF, Burch PA, Sinicrope FA, Diasio RB. The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc. 2010;85:1080-1089. [PMID: 21123634 DOI: 10.4065/mcp.2010.0421] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
138 Yang Y, Zheng J, Li Y. Comparison of 4 lymph node staging systems for the prognostic prediction of esophagogastric junction adenocarcinoma with ≤15 retrieved lymph nodes. Eur J Surg Oncol 2021:S0748-7983(21)00942-2. [PMID: 34876328 DOI: 10.1016/j.ejso.2021.11.133] [Reference Citation Analysis]
139 Smyth EC, Cunningham D. Operable gastro-oesophageal junctional adenocarcinoma: Where to next? World J Gastrointest Oncol 2014; 6(6): 145-155 [PMID: 24936225 DOI: 10.4251/wjgo.v6.i6.145] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
140 Ashok A, Tiwari V, Jiwnani S, Karimundackal G, Pramesh CS. Controversies in preoperative therapy in esophageal cancer: Current evidence and ongoing research. Ann Gastroenterol Surg 2019;3:592-7. [PMID: 31788647 DOI: 10.1002/ags3.12301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
141 van der Wilk BJ, Eyck BM, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer. Dig Surg 2019;36:462-9. [PMID: 30227434 DOI: 10.1159/000493435] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
142 Feng JF, Wang L, Yang X, Jiang YH. Prognostic value of lactate dehydrogenase to albumin ratio (LAR) in patients with resectable esophageal squamous cell carcinoma. Cancer Manag Res 2019;11:7243-51. [PMID: 31447584 DOI: 10.2147/CMAR.S208320] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
143 Lordick F, Gockel I. Chances, risks and limitations of neoadjuvant therapy in surgical oncology. Innov Surg Sci 2016;1:3-11. [PMID: 31579713 DOI: 10.1515/iss-2016-0004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
144 Solomon BL, Garrido-Laguna I. Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future Oncol 2018;14:947-62. [PMID: 29542354 DOI: 10.2217/fon-2017-0597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
145 Harada K, Baba Y, Ishimoto T, Shigaki H, Kosumi K, Yoshida N, Watanabe M, Baba H. The role of microRNA in esophageal squamous cell carcinoma. J Gastroenterol. 2016;51:520-530. [PMID: 26794004 DOI: 10.1007/s00535-016-1161-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 5.8] [Reference Citation Analysis]
146 Reynolds JV, Preston SR, O'Neill B, Baeksgaard L, Griffin SM, Mariette C, Cuffe S, Cunningham M, Crosby T, Parker I, Hofland K, Hanna G, Svendsen LB, Donohoe CL, Muldoon C, O'Toole D, Johnson C, Ravi N, Jones G, Corkhill AK, Illsley M, Mellor J, Lee K, Dib M, Marchesin V, Cunnane M, Scott K, Lawner P, Warren S, O'Reilly S, O'Dowd G, Leonard G, Hennessy B, Dermott RM. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer 2017;17:401. [PMID: 28578652 DOI: 10.1186/s12885-017-3386-2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 15.4] [Reference Citation Analysis]
147 Zheng YZ, Wen J, Cao X, Yang H, Luo KJ, Liu QW, Huang QY, Chen JY, Fu JH. Decreased mRNA expression of transcription factor forkhead box F2 is an indicator of poor prognosis in patients with resected esophageal squamous cell carcinoma. Mol Clin Oncol 2015;3:713-9. [PMID: 26137292 DOI: 10.3892/mco.2015.511] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
148 Powell AGMT, Chin C, Coxon AH, Chalishazar A, Christian A, Roberts SA, Lewis WG. Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma. BJS Open 2020;4:416-23. [PMID: 32232963 DOI: 10.1002/bjs5.50277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
149 Davarzani N, Hewitt LC, Hale MD, Melotte V, Nankivell M, Hutchins GGA, Cunningham D, Allum WH, Langley RE, Jolani S, Grabsch HI. Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trial. Dis Esophagus 2020;33:doaa058. [PMID: 32591823 DOI: 10.1093/dote/doaa058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Sonohara F, Gao F, Iwata N, Kanda M, Koike M, Takahashi N, Yamada Y, Kodera Y, Wang X, Goel A. Genome-wide Discovery of a Novel Gene-expression Signature for the Identification of Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma. Ann Surg 2019;269:879-86. [PMID: 29240008 DOI: 10.1097/SLA.0000000000002622] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
151 Triantafyllou T, Wijnhoven BPL. Current status of esophageal cancer treatment. Chin J Cancer Res 2020;32:271-86. [PMID: 32694894 DOI: 10.21147/j.issn.1000-9604.2020.03.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
152 O'Neill JR, Kennedy ED, Save V, Langdale-Brown B, Wall L, Skipworth RJE, Paterson-Brown S. Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results. Int J Surg Oncol (N Y) 2017;2:e09. [PMID: 29177210 DOI: 10.1097/IJ9.0000000000000009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
153 Ohkura Y, Ueno M, Iizuka T, Haruta S, Tanaka T, Udagawa H. Factors Predicting Effectiveness of Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma. Medicine (Baltimore) 2016;95:e3365. [PMID: 27082598 DOI: 10.1097/MD.0000000000003365] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
154 Murata A, Baba Y, Watanabe M, Shigaki H, Miyake K, Karashima R, Imamura Y, Ida S, Ishimoto T, Iwagami S. p53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma. Med Oncol. 2013;30:728. [PMID: 24026664 DOI: 10.1007/s12032-013-0728-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
155 Sehdev A, Catenacci DV. Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. J Hematol Oncol 2013;6:66. [PMID: 24010946 DOI: 10.1186/1756-8722-6-66] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
156 van den Ende T, Ter Veer E, Mali RMA, van Berge Henegouwen MI, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM. Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E530. [PMID: 31013858 DOI: 10.3390/cancers11040530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
157 Samalin E, Ychou M. Neoadjuvant therapy for gastroesophageal adenocarcinoma. World J Clin Oncol 2016; 7(3): 284-292 [PMID: 27298768 DOI: 10.5306/wjco.v7.i3.284] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
158 Gamboa AC, Meyer BI, Switchenko JM, Rupji M, Lee RM, Turgeon MK, Russell MC, Cardona K, Kooby DA, Maithel SK, Shah MM. Should adenosquamous esophageal cancer be treated like adenocarcinoma or squamous cell carcinoma? J Surg Oncol 2020;122:412-21. [PMID: 32462769 DOI: 10.1002/jso.25990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
159 Yang PW, Hsieh MS, Chang YH, Huang PM, Lee JM. Genetic polymorphisms of ATG5 predict survival and recurrence in patients with early-stage esophageal squamous cell carcinoma. Oncotarget 2017;8:91494-504. [PMID: 29207660 DOI: 10.18632/oncotarget.20793] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
160 Xu FP, Liu YH, Luo XL, Zhang F, Zhou HY, Ge Y, Liu C, Chen J, Luo DL, Yan LX, Mei P, Xu J, Zhuang HG. Overexpression of SRC-3 promotes esophageal squamous cell carcinoma aggressiveness by enhancing cell growth and invasiveness. Cancer Med 2016;5:3500-11. [PMID: 27781415 DOI: 10.1002/cam4.884] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
161 Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA. Customization of therapy for gastroesophageal adenocarcinoma patients. Chronic Dis Transl Med 2018;4:8-17. [PMID: 29756119 DOI: 10.1016/j.cdtm.2018.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 Oh D, Kim JH. The Current Evidence on Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Korean J Thorac Cardiovasc Surg 2020;53:160-7. [PMID: 32793446 DOI: 10.5090/kjtcs.2020.53.4.160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
163 Kosumi K, Baba Y, Ishimoto T, Harada K, Nakamura K, Ohuchi M, Kiyozumi Y, Izumi D, Tokunaga R, Taki K, Higashi T, Miyata T, Shigaki H, Kurashige J, Hiyoshi Y, Iwatsuki M, Iwagami S, Sakamoto Y, Miyamoto Y, Yoshida N, Oki E, Watanabe M, Baba H. APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma. Med Oncol 2016;33:26. [PMID: 26880326 DOI: 10.1007/s12032-016-0739-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
164 Onitilo AA, Stankowski-Drengler TJ, Shiyanbola O, Engel J, Tanimu S, Fagbemi SO, Li YH. Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC). Clin Med Res 2021;19:64-71. [PMID: 33789952 DOI: 10.3121/cmr.2021.1573] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
165 Yang PW, Hsu IJ, Chang CW, Wang YC, Hsieh CY, Shih KH, Wong LF, Shih NY, Hsieh MS, Hou MT, Lee JM. Visible-absorption spectroscopy as a biomarker to predict treatment response and prognosis of surgically resected esophageal cancer. Sci Rep 2016;6:33414. [PMID: 27624872 DOI: 10.1038/srep33414] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
166 Blazeby JM, Strong S, Donovan JL, Wilson C, Hollingworth W, Crosby T, Nicklin J, Falk SJ, Barham CP, Hollowood AD, Streets CG, Titcomb D, Krysztopik R, Griffin SM, Brookes ST. Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer. Br J Cancer 2014;111:234-40. [PMID: 24921919 DOI: 10.1038/bjc.2014.313] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
167 Zhang S, Tan IB, Sapari NS, Grabsch HI, Okines A, Smyth EC, Aoyama T, Hewitt LC, Inam I, Bottomley D, Nankivell M, Stenning SP, Cunningham D, Wotherspoon A, Tsuburaya A, Yoshikawa T, Soong R, Tan P. Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2015;17:242-50. [PMID: 25746798 DOI: 10.1016/j.jmoldx.2014.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
168 Wang Q, Yan Z, Ge L, Li N, Yang M, Sun X, Xie L, Zhang G, Zhu W, Wang Y, Li Y, Li X, Guo X. OSeac: An Online Survival Analysis Tool for Esophageal Adenocarcinoma. Front Oncol 2020;10:315. [PMID: 32211334 DOI: 10.3389/fonc.2020.00315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
169 Namm JP, Posner MC. Transhiatal Esophagectomy for Esophageal Cancer. J Laparoendosc Adv Surg Tech A 2016;26:752-6. [PMID: 27548444 DOI: 10.1089/lap.2016.29009.jpn] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
170 Xu Y, Yu X, Chen Q, Mao W. Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? World J Surg Oncol 2012;10:173. [PMID: 22920951 DOI: 10.1186/1477-7819-10-173] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
171 Linder G, Jestin C, Sundbom M, Hedberg J. Safe Introduction of Minimally Invasive Esophagectomy at a Medium Volume Center. Scand J Surg 2020;109:121-6. [PMID: 30739555 DOI: 10.1177/1457496919826722] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
172 Zhang C, Shi Z, Kalendralis P, Whybra P, Parkinson C, Berbee M, Spezi E, Roberts A, Christian A, Lewis W, Crosby T, Dekker A, Wee L, Foley KG. Prediction of lymph node metastases using pre-treatment PET radiomics of the primary tumour in esophageal adenocarcinoma: an external validation study. Br J Radiol 2021;94:20201042. [PMID: 33264032 DOI: 10.1259/bjr.20201042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Baiocco S, Sah BR, Mallia A, Kelly-Morland C, Neji R, Stirling JJ, Jeljeli S, Bevilacqua A, Cook GJR, Goh V. Exploratory radiomic features from integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging are associated with contemporaneous metastases in oesophageal/gastroesophageal cancer. Eur J Nucl Med Mol Imaging 2019;46:1478-84. [PMID: 30919055 DOI: 10.1007/s00259-019-04306-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
174 Obulkasim A, Ylstra B, van Essen HF, Benner C, Stenning S, Langley R, Allum W, Cunningham D, Inam I, Hewitt LC, West NP, Meijer GA, van de Wiel MA, Grabsch HI. Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma. Oncotarget 2016;7:44084-95. [PMID: 27286451 DOI: 10.18632/oncotarget.9857] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
175 Matsuda S, Takeuchi H, Kawakubo H, Ando N, Kitagawa Y. Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan. Ann Thorac Cardiovasc Surg 2016;22:275-83. [PMID: 27384595 DOI: 10.5761/atcs.ra.16-00111] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
176 Zhu Y, Liu M, Yun X, Wang D, Bai Y, Zhang G, Ji B, Jing C. Meta-Analysis for the Therapeutic Effect of Neoadjuvant Therapy in Resectable Esophageal Cancer. Pathol Oncol Res 2017;23:657-63. [PMID: 28013492 DOI: 10.1007/s12253-016-0164-4] [Reference Citation Analysis]
177 Li S, Wang Z, Huang J, Cheng S, Du H, Che G, Peng Y. Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis. BMC Cancer 2016;16:877. [PMID: 27835987 DOI: 10.1186/s12885-016-2940-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
178 Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol 2011;5:89-99. [PMID: 21603244 DOI: 10.4137/CMO.S6983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
179 Noordman BJ, Shapiro J, Spaander MC, Krishnadath KK, van Laarhoven HW, van Berge Henegouwen MI, Nieuwenhuijzen GA, van Hillegersberg R, Sosef MN, Steyerberg EW, Wijnhoven BP, van Lanschot JJ; SANO study group. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol. JMIR Res Protoc 2015;4:e79. [PMID: 26121676 DOI: 10.2196/resprot.4320] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 6.7] [Reference Citation Analysis]
180 Lagarde SM, Phillips AW, Navidi M, Disep B, Immanuel A, Griffin SM. The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence. Br J Cancer. 2015;113:1427-1433. [PMID: 26554656 DOI: 10.1038/bjc.2015.354] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
181 Elimova E, Mizrak Kaya D, Harada K, Ajani JA. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clin Proc 2016;91:1307-18. [PMID: 27594190 DOI: 10.1016/j.mayocp.2016.07.018] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
182 Chen MF, Kuan FC, Yen TC, Lu MS, Lin PY, Chung YH, Chen WC, Lee KD. IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. Oncotarget. 2014;5:8716-8728. [PMID: 25238263 DOI: 10.18632/oncotarget.2368] [Cited by in Crossref: 92] [Cited by in F6Publishing: 94] [Article Influence: 13.1] [Reference Citation Analysis]
183 Cho WK, Oh D, Ahn YC, Shim YM, Zo JI, Sun JM, Ahn MJ, Park K. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery. Oncotarget 2017;8:3542-52. [PMID: 27682879 DOI: 10.18632/oncotarget.12200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
184 Ma Z, Yuan M, Bao Y, Wang Y, Men Y, Hui Z. Survival of Neoadjuvant and Adjuvant Therapy Compared With Surgery Alone for Resectable Esophageal Squamous Cell Carcinoma: A Systemic Review and Network Meta-Analysis. Front Oncol 2021;11:728185. [PMID: 34745950 DOI: 10.3389/fonc.2021.728185] [Reference Citation Analysis]
185 Tanaka Y, Takahashi T, Yamaguchi K, Osada S, Shimokawa T, Yoshida K. Elemental diet plus glutamine for the prevention of mucositis in esophageal cancer patients receiving chemotherapy: a feasibility study. Support Care Cancer 2016;24:933-41. [PMID: 26266659 DOI: 10.1007/s00520-015-2864-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
186 Jiang D, He Z, Wang C, Zhou Y, Li F, Pu W, Zhang X, Feng X, Zhang M, Yecheng X, Xu Y, Jin L, Guo S, Wang J, Wang M. Epigenetic silencing of ZNF132 mediated by methylation-sensitive Sp1 binding promotes cancer progression in esophageal squamous cell carcinoma. Cell Death Dis 2018;10:1. [PMID: 30578410 DOI: 10.1038/s41419-018-1236-z] [Cited by in Crossref: 104] [Cited by in F6Publishing: 47] [Article Influence: 26.0] [Reference Citation Analysis]
187 Alsina M, Rivera F, Ramos FJ, Galán M, López R, García-Alfonso P, Alés-Martinez JE, Queralt B, Antón A, Carrato A, Grávalos C, Méndez-Vidal MJ, López C, de Mena IR, Tabernero J, Giralt J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR). A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. Target Oncol 2018;13:69-78. [PMID: 29128908 DOI: 10.1007/s11523-017-0536-z] [Reference Citation Analysis]
188 Purwar P, Bambarkar S, Jiwnani S, Karimundackal G, Laskar SG, Pramesh CS. Multimodality management of esophageal cancer. Indian J Surg 2014;76:494-503. [PMID: 25614726 DOI: 10.1007/s12262-014-1163-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
189 Chen JW, Xie JD, Ling YH, Li P, Yan SM, Xi SY, Luo RZ, Yun JP, Xie D, Cai MY. The prognostic effect of perineural invasion in esophageal squamous cell carcinoma. BMC Cancer. 2014;14:313. [PMID: 24886020 DOI: 10.1186/1471-2407-14-313] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
190 Gao HJ, Wei YC, Gong L, Ge N, Han B, Shi GD, Yu ZT. Role of radiation therapy in node-negative esophageal cancer: A propensity-matched analysis. Thorac Cancer 2020;11:2820-9. [PMID: 32790041 DOI: 10.1111/1759-7714.13607] [Reference Citation Analysis]
191 Shang QX, Wang YC, Yang YS, Hu WP, Chen LQ. Pattern of subcarinal lymph node metastasis and dissection strategy for thoracic esophageal cancer. J Thorac Dis 2020;12:5667-77. [PMID: 33209399 DOI: 10.21037/jtd-20-1776] [Reference Citation Analysis]
192 Harrington C, Smith L, Bisland J, López González E, Jamieson N, Paterson S, Stanley AJ. Mediastinal node staging by positron emission tomography-computed tomography and selective endoscopic ultrasound with fine needle aspiration for patients with upper gastrointestinal cancer: Results from a regional centre. World J Gastrointest Endosc 2018; 10(1): 37-44 [PMID: 29375740 DOI: 10.4253/wjge.v10.i1.37] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
193 Fornari F, Wagner R. Update on endoscopic diagnosis, management and surveillance strategies of esophageal diseases. World J Gastrointest Endosc 2012; 4(4): 117-122 [PMID: 22523612 DOI: 10.4253/wjge.v4.i4.117] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
194 Schuhmacher C, Novotny A, Meyer HJ. [Treatment of gastric cancer beyond current guideline: state of the art]. Chirurg 2013;84:310-5. [PMID: 23479274 DOI: 10.1007/s00104-012-2454-z] [Reference Citation Analysis]
195 Foley KG, Lavery A, Napier E, Campbell D, Eatock MM, Kennedy RD, Bradley KM, Turkington RC. A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma. Sci Rep 2021;11:13061. [PMID: 34158588 DOI: 10.1038/s41598-021-92545-w] [Reference Citation Analysis]
196 Baba Y, Watanabe M, Yoshida N, Baba H. Neoadjuvant treatment for esophageal squamous cell carcinoma. World J Gastrointest Oncol 2014; 6(5): 121-128 [PMID: 24834142 DOI: 10.4251/wjgo.v6.i5.121] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
197 Huang YC, Lu HI, Huang SC, Hsu CC, Chiu NT, Wang YM, Chiu YC, Li SH. FDG PET using SUVmax for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy. BMC Med Imaging 2017;17:1. [PMID: 28056868 DOI: 10.1186/s12880-016-0171-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
198 Mishra S, Ahmad F, Singh S, Singh RK, Das KJM, Kumar S. Assessing failure patterns of radical intent radiation strategies in patients with locally advanced carcinoma of the esophagus. Cancer Rep (Hoboken) 2021;4:e1332. [PMID: 33369258 DOI: 10.1002/cnr2.1332] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
199 Vos EL, Carr RA, Hsu M, Nakauchi M, Nobel T, Russo A, Barbetta A, Tan KS, Tang L, Ilson D, Ku GY, Wu AJ, Janjigian YY, Yoon SS, Bains MS, Jones DR, Coit D, Molena D, Strong VE. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma. Br J Surg 2021;108:1332-40. [PMID: 34476473 DOI: 10.1093/bjs/znab228] [Reference Citation Analysis]
200 Song Q, Wu JZ, Wang S, Chen WH. Elevated preoperative platelet distribution width predicts poor prognosis in Esophageal Squamous Cell Carcinoma. Sci Rep 2019;9:15234. [PMID: 31645619 DOI: 10.1038/s41598-019-51675-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
201 Zheng ZY, Yang PL, Luo W, Yu SX, Xu HY, Huang Y, Li RY, Chen Y, Xu XE, Liao LD, Wang SH, Huang HC, Li EM, Xu LY. STAT3β Enhances Sensitivity to Concurrent Chemoradiotherapy by Inducing Cellular Necroptosis in Esophageal Squamous Cell Carcinoma. Cancers (Basel) 2021;13:901. [PMID: 33670049 DOI: 10.3390/cancers13040901] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
202 Mariette C. What is the optimal neoadjuvant treatment for locally advanced oesophageal adenocarcinoma? Ann Oncol 2017;28:447-50. [PMID: 27993810 DOI: 10.1093/annonc/mdw644] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
203 Kamarajah SK, Madhavan A, Chmelo J, Navidi M, Wahed S, Immanuel A, Hayes N, Griffin SM, Phillips AW. Impact of Smoking Status on Perioperative Morbidity, Mortality, and Long-Term Survival Following Transthoracic Esophagectomy for Esophageal Cancer. Ann Surg Oncol 2021;28:4905-15. [PMID: 33660129 DOI: 10.1245/s10434-021-09720-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Ford H, Gounaris I. Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma. Therap Adv Gastroenterol 2015;8:189-205. [PMID: 26136837 DOI: 10.1177/1756283X15585468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
205 Smyth E, Knödler M, Giraut A, Mauer M, Nilsson M, Van Grieken N, Wagner AD, Moehler M, Lordick F. VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study. Front Oncol 2019;9:1320. [PMID: 32083013 DOI: 10.3389/fonc.2019.01320] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
206 DaVee T, Ajani JA, Lee JH. Is endoscopic ultrasound examination necessary in the management of esophageal cancer? World J Gastroenterol 2017; 23(5): 751-762 [PMID: 28223720 DOI: 10.3748/wjg.v23.i5.751] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
207 Li J, Ma S. History and current situation of neoadjuvant treatment for locally advanced esophageal cancer. Thorac Cancer 2021;12:2293-9. [PMID: 34254738 DOI: 10.1111/1759-7714.14069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
208 Thomas A, Virdee PS, Eatock M, Lord SR, Falk S, Anthoney DA, Turkington RC, Goff M, Elhussein L, Collins L, Love S, Moschandreas J, Middleton MR. Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma. Eur J Cancer 2020;124:131-41. [PMID: 31765988 DOI: 10.1016/j.ejca.2019.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
209 Satomi T, Kawano S, Inaba T, Nakagawa M, Mouri H, Yoshioka M, Tanaka S, Toyokawa T, Kobayashi S, Tanaka T, Kanzaki H, Iwamuro M, Kawahara Y, Okada H. Efficacy and safety of endoscopic submucosal dissection for gastric tube cancer: A multicenter retrospective study. World J Gastroenterol 2021; 27(11): 1043-1054 [PMID: 33776371 DOI: 10.3748/wjg.v27.i11.1043] [Reference Citation Analysis]
210 Iams WT, Villaflor VM. Neoadjuvant Treatment for Locally Invasive Esophageal Cancer. World J Surg 2017;41:1719-25. [PMID: 28271259 DOI: 10.1007/s00268-017-3959-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
211 Niwa Y, Yamada S, Sonohara F, Kurimoto K, Hayashi M, Tashiro M, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y. Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy. J Transl Med 2019;17:1. [PMID: 30602370 DOI: 10.1186/s12967-018-1762-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
212 Boonstra JJ, Kok TC, Wijnhoven BP, van Heijl M, van Berge Henegouwen MI, Ten Kate FJ, Siersema PD, Dinjens WN, van Lanschot JJ, Tilanus HW, van der Gaast A. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer. 2011;11:181. [PMID: 21595951 DOI: 10.1186/1471-2407-11-181] [Cited by in Crossref: 96] [Cited by in F6Publishing: 87] [Article Influence: 8.7] [Reference Citation Analysis]
213 Hewitt LC, Inam IZ, Saito Y, Yoshikawa T, Quaas A, Hoelscher A, Bollschweiler E, Fazzi GE, Melotte V, Langley RE, Nankivell M, Cunningham D, Allum W, Hutchins GG, Grabsch HI. Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. Eur J Cancer 2018;94:104-14. [PMID: 29550565 DOI: 10.1016/j.ejca.2018.02.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
214 Al-Attar A, Gossage L, Fareed KR, Shehata M, Mohammed M, Zaitoun AM, Soomro I, Lobo DN, Abbotts R, Chan S, Madhusudan S. Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br J Cancer 2010;102:704-9. [PMID: 20087352 DOI: 10.1038/sj.bjc.6605541] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 4.5] [Reference Citation Analysis]
215 Jing W, Guo H, Kong L, Zhang Y, Wang H, An C, Zhu H, Yu J. Clinical outcomes of elderly patients (≥70 years) with resectable esophageal squamous cell carcinoma who underwent esophagectomy or chemoradiotherapy: A retrospective analysis from a single cancer institute. Medicine (Baltimore) 2016;95:e5630. [PMID: 27977606 DOI: 10.1097/MD.0000000000005630] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Lopes AB, Fagundes RB. Esophageal squamous cell carcinoma - precursor lesions and early diagnosis. World J Gastrointest Endosc 2012; 4(1): 9-16 [PMID: 22267978 DOI: 10.4253/wjge.v4.i1.9] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
217 Esaki M, Suzuki S, Hayashi Y, Yokoyama A, Abe S, Hosokawa T, Tsuruta S, Minoda Y, Hata Y, Ogino H, Akiho H, Ihara E, Ogawa Y. Propensity score-matching analysis to compare clinical outcomes of endoscopic submucosal dissection for early gastric cancer in the postoperative and non-operative stomachs. BMC Gastroenterol 2018;18:125. [PMID: 30081824 DOI: 10.1186/s12876-018-0855-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
218 Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048. [PMID: 28748917 DOI: 10.1038/nrdp.2017.48] [Cited by in Crossref: 249] [Cited by in F6Publishing: 246] [Article Influence: 49.8] [Reference Citation Analysis]
219 Zhang G, Kong X, Wang M, Zhao H, Han S, Hu R, Huang J, Cui W. AXL is a marker for epithelial-mesenchymal transition in esophageal squamous cell carcinoma. Oncol Lett 2018;15:1900-6. [PMID: 29434888 DOI: 10.3892/ol.2017.7443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
220 Cartwright E, Cunningham D. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. Curr Treat Options Oncol 2017;18:69. [PMID: 29143893 DOI: 10.1007/s11864-017-0510-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
221 Zhou W, Wu J, Liu X, Ni M, Meng Z, Liu S, Jia S, Zhang J, Guo S, Zhang X. Identification of crucial genes correlated with esophageal cancer by integrated high-throughput data analysis. Medicine (Baltimore) 2020;99:e20340. [PMID: 32443386 DOI: 10.1097/MD.0000000000020340] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
222 Cui XB, Shen YY, Jin TT, Li S, Li TT, Zhang SM, Peng H, Liu CX, Li SG, Yang L, Li N, Hu JM, Jiang JF, Li M, Liang WH, Li Y, Wei YT, Sun ZZ, Wu CY, Chen YZ, Li F. SLC39A6: a potential target for diagnosis and therapy of esophageal carcinoma. J Transl Med 2015;13:321. [PMID: 26444413 DOI: 10.1186/s12967-015-0681-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
223 Matsuda S, Kawakubo H, Irino T, Kitagawa Y. Role sharing between minimally invasive oesophagectomy and organ preservation approach for surgically resectable advanced oesophageal cancer. Jpn J Clin Oncol 2021:hyab192. [PMID: 34891170 DOI: 10.1093/jjco/hyab192] [Reference Citation Analysis]
224 Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee KD. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer 2013;12:26. [PMID: 23561329 DOI: 10.1186/1476-4598-12-26] [Cited by in Crossref: 82] [Cited by in F6Publishing: 82] [Article Influence: 9.1] [Reference Citation Analysis]
225 Garg PK, Sharma J, Jakhetiya A, Goel A, Gaur MK. Preoperative therapy in locally advanced esophageal cancer. World J Gastroenterol 2016; 22(39): 8750-8759 [PMID: 27818590 DOI: 10.3748/wjg.v22.i39.8750] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
226 Kleinberg LR, Catalano PJ, Forastiere AA, Keller SM, Mitchel EP, Anne PR, Benson AB 3rd. Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design. Int J Radiat Oncol Biol Phys 2016;94:738-46. [PMID: 26972646 DOI: 10.1016/j.ijrobp.2015.12.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
227 Fareed KR, Al-Attar A, Soomro IN, Kaye PV, Patel J, Lobo DN, Parsons SL, Madhusudan S. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer. 2010;102:1600-1607. [PMID: 20461087 DOI: 10.1038/sj.bjc.6605686] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
228 Fukahori M, Kato K, Taniguchi H, Ohtomo R, Takahashi N, Shoji H, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Yamada Y, Shimada Y, Ito Y, Itami J, Hokamura N, Igaki H, Tachimori Y, Miwa K, Torimura T, Boku N. Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations. Mol Clin Oncol 2021;14:41. [PMID: 33437479 DOI: 10.3892/mco.2020.2205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
229 Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2012;23:2638-42. [PMID: 22831985 DOI: 10.1093/annonc/mds210] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 4.7] [Reference Citation Analysis]
230 McNamara MJ, Adelstein DJ. Current developments in the management of locally advanced esophageal cancer. Curr Oncol Rep. 2012;14:342-349. [PMID: 22544559 DOI: 10.1007/s11912-012-0239-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
231 Sharma B, Raina S, Sharma R, Bodh V, Raina SK, Sharma N. Self-Expanding Metallic Stents (SEMS) in Inoperable Esophageal Cancer: A Prospective Analysis of Morbidity and Survival Outcomes. Indian J Palliat Care 2019;25:398-402. [PMID: 31413455 DOI: 10.4103/IJPC.IJPC_185_18] [Reference Citation Analysis]
232 Botha AJ, Odendaal W, Patel V, Watcyn-Jones T, Mahadeva U, Chang F, Deere H. Total adventitial resection of the cardia: 'optimal local resection' for tumours of the oesophagogastric junction. Ann R Coll Surg Engl 2011;93:608-14. [PMID: 22041237 DOI: 10.1308/003588411X13165261994111] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
233 Faluyi OO, Eng L, Qiu X, Che J, Zhang Q, Cheng D, Ying N, Tse A, Kuang Q, Dodbiba L, Renouf DJ, Marsh S, Savas S, Mackay HJ, Knox JJ, Darling GE, Wong RK, Xu W, Azad AK, Liu G. Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival. Cancer Med. 2017;6:361-373. [PMID: 28074552 DOI: 10.1002/cam4.989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
234 Secrier M, Li X, de Silva N, Eldridge MD, Contino G, Bornschein J, MacRae S, Grehan N, O'Donovan M, Miremadi A, Yang TP, Bower L, Chettouh H, Crawte J, Galeano-Dalmau N, Grabowska A, Saunders J, Underwood T, Waddell N, Barbour AP, Nutzinger B, Achilleos A, Edwards PA, Lynch AG, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet 2016;48:1131-41. [PMID: 27595477 DOI: 10.1038/ng.3659] [Cited by in Crossref: 202] [Cited by in F6Publishing: 188] [Article Influence: 33.7] [Reference Citation Analysis]
235 Gemici C, Yaprak G, Batirel HF, Ilhan M, Mayadagli A. Radiation field size and dose determine oncologic outcome in esophageal cancer. World J Surg Oncol 2016;14:263. [PMID: 27737673 DOI: 10.1186/s12957-016-1024-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
236 Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-5218. [PMID: 21060024 DOI: 10.1200/jco.2009.26.6114] [Cited by in Crossref: 387] [Cited by in F6Publishing: 204] [Article Influence: 32.3] [Reference Citation Analysis]
237 Hsieh JC, Chiang PC, Hung TM, Chao YK, Kuo YC, Wen CT, Su PJ, Peng MT, Chen HW, Liu HL, Chang HK, Wu MH, Wang HM. Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence. Cancer Med 2021;10:8300-9. [PMID: 34706159 DOI: 10.1002/cam4.4025] [Reference Citation Analysis]
238 Wei MT, Zhang YC, Deng XB, Yang TH, He YZ, Wang ZQ. Transthoracic vs transhiatal surgery for cancer of the esophagogastric junction: A meta-analysis. World J Gastroenterol 2014; 20(29): 10183-10192 [PMID: 25110447 DOI: 10.3748/wjg.v20.i29.10183] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
239 Geeraerts M, Silva Corten LC, van Det M, Luyer M, Nieuwenhuijzen G, Vermeer M, Ruurda J, van Hillegersberg R, Kouwenhoven E. Insights in work rehabilitation after minimally invasive esophagectomy. Surg Endosc 2019;33:3457-63. [PMID: 30694387 DOI: 10.1007/s00464-018-06626-5] [Reference Citation Analysis]
240 Vošmik M, Kopecký J, John S, Kubeček O, Lochman P, Banni AM, Hruška L, Sirák I. Combined Therapy of Locally Advanced Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors. Cancers (Basel) 2021;13:4591. [PMID: 34572818 DOI: 10.3390/cancers13184591] [Reference Citation Analysis]
241 Lim JH, Lee SA, Kang GE, Kim JM, Park JK, Chung YJ, Jung JK, Park CK, Kim HS, Lee DW. Esophageal cancer treated by endoscopic submucosal dissection after neoadjuvant chemoradiotherapy: a case report. J Med Case Rep 2014;8:439. [PMID: 25519497 DOI: 10.1186/1752-1947-8-439] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
242 Lerttanatum N, Tharavej C, Chongpison Y, Sanpavat A. Comparison of tumor regression grading system in locally advanced esophageal squamous cell carcinoma after preoperative radio-chemotherapy to determine the most accurate system predicting prognosis. J Gastrointest Oncol 2019;10:276-82. [PMID: 31032095 DOI: 10.21037/jgo.2018.12.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
243 Huang C, Wang L, Yang X, Lai L, Chen D, Duan C. Expression of activated signal transducer and activator of transcription-3 as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma. World J Surg Oncol 2015;13:314. [PMID: 26553224 DOI: 10.1186/s12957-015-0726-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
244 Kato H, Nakajima M. Treatments for esophageal cancer: a review. Gen Thorac Cardiovasc Surg 2013;61:330-5. [PMID: 23568356 DOI: 10.1007/s11748-013-0246-0] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 8.7] [Reference Citation Analysis]
245 McMenamin ÚC, Trainor J, Coleman HG, McManus DT, McQuaid S, Bingham V, James J, Salto-Tellez M, Johnston BT, Turkington RC. Sex hormone receptor expression and survival in esophageal adenocarcinoma: a prospective cohort study. Oncotarget 2018;9:35300-12. [PMID: 30450159 DOI: 10.18632/oncotarget.26236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
246 Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist. 2011;16:844-858. [PMID: 21632459 DOI: 10.1634/thenocoligist.2010-0387] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
247 Ben-David K, Sarosi GA, Cendan JC, Howard D, Rossidis G, Hochwald SN. Decreasing morbidity and mortality in 100 consecutive minimally invasive esophagectomies. Surg Endosc. 2012;26:162-167. [PMID: 21792712 DOI: 10.1007/s00464-011-1846-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
248 Lin D, Ma L, Ye T, Pan Y, Shao L, Song Z, Jiang S, Chen H, Xiang J. Results of neoadjuvant therapy followed by esophagectomy for patients with locally advanced thoracic esophageal squamous cell carcinoma. J Thorac Dis 2017;9:318-26. [PMID: 28275480 DOI: 10.21037/jtd.2017.02.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
249 Keditsu KK, Jiwnani S, Karimundackal G, Pramesh CS. Multimodality management of esophageal cancer. Indian J Surg Oncol. 2013;4:96-104. [PMID: 24426708 DOI: 10.1007/s13193-013-0216-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
250 Altorki N, Harrison S. What is the role of neoadjuvant chemotherapy, radiation, and adjuvant treatment in resectable esophageal cancer? Ann Cardiothorac Surg. 2017;6:167-174. [PMID: 28447006 DOI: 10.21037/acs.2017.03.16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
251 Jin YQ, Miao DL. Multiomic Analysis of Methylation and Transcriptome Reveals a Novel Signature in Esophageal Cancer. Dose Response 2020;18:1559325820942075. [PMID: 32728353 DOI: 10.1177/1559325820942075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
252 Song Q, Wu JZ, Wang S. Postoperative Monocyte Count Change Is a Better Predictor of Survival Than Preoperative Monocyte Count in Esophageal Squamous Cell Carcinoma. Biomed Res Int 2019;2019:2702719. [PMID: 31485440 DOI: 10.1155/2019/2702719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
253 Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep 2011;13:157-67. [PMID: 21365188 DOI: 10.1007/s11912-011-0158-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
254 Rocha-Filho DR, Peixoto RD, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Di Paula Filho RP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Ribeiro U Jr, Jesus VHF, Costa WL Jr, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience 2021;15:1195. [PMID: 33889204 DOI: 10.3332/ecancer.2021.1195] [Reference Citation Analysis]
255 Davarzani N, Hutchins GGA, West NP, Hewitt LC, Nankivell M, Cunningham D, Allum WH, Smyth E, Valeri N, Langley RE, Grabsch HI. Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial. Histopathology 2018;72:1180-8. [PMID: 29465751 DOI: 10.1111/his.13491] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
256 Stroes CI, Schokker S, Molenaar RJ, Mathôt RAA, Bijlsma MF, van der Woude SO, Belo Pereira JP, Hooijer GKJ, Verhoeven RHA, Cats A, Grootscholten C, van Sandick JW, Creemers GJ, Nieuwenhuijzen GAP, Haj Mohammad N, Ruurda JP, Meijer SL, Hulshof MCCM, van Berge Henegouwen MI, van Laarhoven HWM. A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers (Basel) 2021;13:839. [PMID: 33671266 DOI: 10.3390/cancers13040839] [Reference Citation Analysis]
257 Curtis NJ, Noble F, Bailey IS, Kelly JJ, Byrne JP, Underwood TJ. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction. J Surg Oncol. 2014;109:202-207. [PMID: 24243140 DOI: 10.1002/jso.23484] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
258 Münch S, Habermehl D, Agha A, Belka C, Combs SE, Eckel R, Friess H, Gerbes A, Nüssler NC, Schepp W, Schmid RM, Schmitt W, Schubert-Fritschle G, Weber B, Werner J, Engel J. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry. Strahlenther Onkol 2018;194:125-35. [PMID: 29071366 DOI: 10.1007/s00066-017-1225-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
259 Guo X, Wang Y, Zhang H, Qin C, Cheng A, Liu J, Dai X, Wang Z. Identification of the Prognostic Value of Immune-Related Genes in Esophageal Cancer. Front Genet 2020;11:989. [PMID: 32973887 DOI: 10.3389/fgene.2020.00989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
260 Moehler M, Baltin CTH, Ebert M, Fischbach W, Gockel I, Grenacher L, Hölscher AH, Lordick F, Malfertheiner P, Messmann H, Meyer H, Palmqvist A, Röcken C, Schuhmacher C, Stahl M, Stuschke M, Vieth M, Wittekind C, Wagner D, Mönig SP. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer 2015;18:550-63. [DOI: 10.1007/s10120-014-0403-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
261 Chen MF, Chen PT, Lu MS, Lee CP, Chen WC. Survival benefit of surgery to patients with esophageal squamous cell carcinoma. Sci Rep 2017;7:46139. [PMID: 28383075 DOI: 10.1038/srep46139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
262 Zhao Y, Wang Y, Shan L, Peng C, Zhang W, Zhao X. A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus. Sci Rep 2021;11:6800. [PMID: 33762694 DOI: 10.1038/s41598-021-86102-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Zhou F, Zhu M, Wang M, Qiu L, Cheng L, Jia M, Xiang J, Wei Q. Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy. J Transl Med. 2016;14:154. [PMID: 27246611 DOI: 10.1186/s12967-016-0903-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
264 Watanabe K, Hikichi T, Nakamura J, Hashimoto M, Takagi T, Suzuki R, Sugimoto M, Kikuchi H, Konno N, Takasumi M, Sato Y, Irie H, Obara K, Ohira H. Clinical Outcomes and Adverse Events of Endoscopic Submucosal Dissection for Gastric Tube Cancer after Esophagectomy. Gastroenterol Res Pract 2019;2019:2836860. [PMID: 30944559 DOI: 10.1155/2019/2836860] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
265 Moorcraft SY, Smyth EC, Cunningham D. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? Gastric Cancer 2015;18:1-10. [PMID: 24638977 DOI: 10.1007/s10120-014-0356-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
266 Ishikawa T, Yasuda T, Okayama T, Dohi O, Yoshida N, Kamada K, Uchiyama K, Takagi T, Konishi H, Shiozaki A, Fujiwara H, Konishi H, Naito Y, Teramukai S, Itoh Y. Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study. Cancer Sci 2019;110:3754-60. [PMID: 31646714 DOI: 10.1111/cas.14218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
267 Rhodin KE, Raman V, Jawitz OK, Voigt SL, Farrow NE, Harpole DH, Tong BC, D'Amico TA. Patterns of Use of Induction Therapy for T2N0 Esophageal Cancer. Ann Thorac Surg 2021;111:440-7. [PMID: 32681837 DOI: 10.1016/j.athoracsur.2020.05.089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
268 Sharma P, Saraya A, Sharma R. Potential diagnostic implications of miR-144 overexpression in human oesophageal cancer. Indian J Med Res 2016;143:S91-S103. [PMID: 27748283 DOI: 10.4103/0971-5916.191796] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
269 Harada K, Mizrak Kaya D, Baba H, Ajani JA. Recent advances in preoperative management of esophageal adenocarcinoma. F1000Res 2017;6:501. [PMID: 28491289 DOI: 10.12688/f1000research.10794.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
270 Schulze B, Bergis D, Balermpas P, Trojan J, Woeste G, Bechstein WO, Rödel C, Weiss C. Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis. Oncol Lett 2014;7:534-40. [PMID: 24396483 DOI: 10.3892/ol.2013.1709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
271 Kidane B, Coughlin S, Vogt K, Malthaner R. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev. 2015;CD001556. [PMID: 25988291 DOI: 10.1002/14651858.cd001556.pub3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
272 Tu CC, Hsu PK. The frontline of esophageal cancer treatment: questions to be asked and answered. Ann Transl Med 2018;6:83. [PMID: 29666806 DOI: 10.21037/atm.2017.10.31] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
273 Wang T, Yu J, Liu M, Chen Y, Zhu C, Lu L, Wang M, Min L, Liu X, Zhang X, Gubat JA, Chen Y. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies. Drug Des Devel Ther 2019;13:539-53. [PMID: 30787595 DOI: 10.2147/DDDT.S189514] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
274 Jamel S, Markar SR. Salvage esophagectomy: safe therapeutic strategy? J Thorac Dis 2017;9:S799-808. [PMID: 28815077 DOI: 10.21037/jtd.2017.05.09] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
275 Song Q, Wu JZ, Wang S. Low Preoperative Lymphocyte to Monocyte Ratio Serves as a Worse Prognostic Marker in Patients with Esophageal Squamous Cell Carcinoma Undergoing Curative Tumor Resection. J Cancer 2019;10:2057-62. [PMID: 31205566 DOI: 10.7150/jca.29383] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
276 Murata A, Baba Y, Ishimoto T, Miyake K, Kosumi K, Harada K, Kurashige J, Iwagami S, Sakamoto Y, Miyamoto Y, Yoshida N, Yamamoto M, Oda S, Watanabe M, Nakao M, Baba H. TET family proteins and 5-hydroxymethylcytosine in esophageal squamous cell carcinoma. Oncotarget 2015;6:23372-82. [PMID: 26093090 DOI: 10.18632/oncotarget.4281] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 5.5] [Reference Citation Analysis]
277 Ashraf N, Hoffe S, Kim R. Locally advanced gastroesophageal junction tumor: a treatment dilemma. Oncologist 2015;20:134-42. [PMID: 25561508 DOI: 10.1634/theoncologist.2014-0377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
278 Nakamura K, Baba Y, Kosumi K, Harada K, Shigaki H, Miyake K, Kiyozumi Y, Ohuchi M, Kurashige J, Ishimoto T, Iwatsuki M, Sakamoto Y, Yoshida N, Watanabe M, Nakao M, Baba H. UHRF1 regulates global DNA hypomethylation and is associated with poor prognosis in esophageal squamous cell carcinoma. Oncotarget 2016;7:57821-31. [PMID: 27507047 DOI: 10.18632/oncotarget.11067] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
279 Worni M, Martin J, Gloor B, Pietrobon R, D'Amico TA, Akushevich I, Berry MF. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. J Am Coll Surg 2012;215:643-51. [PMID: 23084493 DOI: 10.1016/j.jamcollsurg.2012.07.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
280 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 2011;71:541-55. [PMID: 21443280 DOI: 10.2165/11585460-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
281 Koemans WJ, Larue RTHM, Kloft M, Ruisch JE, Compter I, Riedl RG, Heij LR, van Elmpt W, Berbée M, Buijsen J, Lambin P, Sosef MN, Grabsch HI. Lymph node response to chemoradiotherapy in oesophageal cancer patients: relationship with radiotherapy fields. Esophagus 2021;18:100-10. [PMID: 32889674 DOI: 10.1007/s10388-020-00777-y] [Reference Citation Analysis]
282 Kamarajah SK, Navidi M, Wahed S, Immanuel A, Hayes N, Griffin SM, Phillips AW. Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction. Ann Surg Oncol 2020;27:3182-92. [PMID: 32201923 DOI: 10.1245/s10434-020-08358-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
283 Gallego J, Cervantes A, Pericay C, Isla D. SEOM clinical guidelines for the treatment of oesophageal cancer. Clin Transl Oncol 2011;13:520-4. [PMID: 21821484 DOI: 10.1007/s12094-011-0691-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
284 Lin CH, Hung TM, Chang YC, Hsieh CH, Shih MC, Huang SM, Yang CK, Chang CF, Chan SC, Yap WK. Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy. Cancers (Basel) 2020;12:E607. [PMID: 32155748 DOI: 10.3390/cancers12030607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
285 Liu J, Cai X, Liu Q, Li H, Cheng Y, Fu X. Characteristics of the local recurrence pattern after curative resection and values in target region delineation in postoperative radiotherapy for lower thoracic esophageal squamous cell cancer. Thorac Cancer. 2017;8:630-633. [PMID: 28941320 DOI: 10.1111/1759-7714.12499] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
286 Yano M, Miyata H, Sugimura K, Motoori M, Omori T, Fujiwara Y, Miyoshi N, Yasui M, Ohue M, Akita H, Tomokuni A, Takahashi H, Kobayashi S, Sakon M. 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the prediction of survival in patients with advanced esophageal cancer who have undergone neoadjuvant chemotherapy. Mol Clin Oncol 2018;8:434-40. [PMID: 29456850 DOI: 10.3892/mco.2018.1546] [Reference Citation Analysis]
287 Takahashi T, Yamahsita S, Matsuda Y, Kishino T, Nakajima T, Kushima R, Kato K, Igaki H, Tachimori Y, Osugi H, Nagino M, Ushijima T. ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. J Cancer Res Clin Oncol 2015;141:453-63. [PMID: 25273507 DOI: 10.1007/s00432-014-1841-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
288 Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-5218. [PMID: 21060024 DOI: 10.1200/jco2009.26.6114] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
289 Low DE. Update on staging and surgical treatment options for esophageal cancer. J Gastrointest Surg 2011;15:719-29. [PMID: 21487832 DOI: 10.1007/s11605-011-1515-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
290 Hurt CN, Nixon LS, Griffiths GO, Al-Mokhtar R, Gollins S, Staffurth JN, Phillips CJ, Blazeby JM, Crosby TD. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer. 2011;11:466. [PMID: 22035459 DOI: 10.1186/1471-2407-11-466] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
291 Wang F, Gao SG, Xue Q, Tan FW, Gao YS, Wang DL, Mao YS, Zhao J, Li Y, Yu XY, Cheng H, Zhao CG, Yang D, Mu JW. Nomogram for predicting the overall survival of the patients with oesophageal signet ring cell carcinoma. J Thorac Dis 2021;13:1315-26. [PMID: 33841925 DOI: 10.21037/jtd-20-3084] [Reference Citation Analysis]
292 Donohoe CL, Reynolds JV. Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials. J Thorac Dis 2017;9:S697-704. [PMID: 28815065 DOI: 10.21037/jtd.2017.03.159] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
293 Mungo B, Molena D, Stem M, Yang SC, Battafarano RJ, Brock MV, Lidor AO. Does neoadjuvant therapy for esophageal cancer increase postoperative morbidity or mortality? Dis Esophagus. 2015;28:644-651. [PMID: 25059343 DOI: 10.1111/dote.12251] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
294 Depypere L, Thomas M, Moons J, Coosemans W, Lerut T, Prenen H, Haustermans K, Van Veer H, Nafteux P. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy. World J Surg Oncol 2019;17:89. [PMID: 31133018 DOI: 10.1186/s12957-019-1630-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
295 Sah BR, Owczarczyk K, Siddique M, Cook GJR, Goh V. Radiomics in esophageal and gastric cancer. Abdom Radiol (NY) 2019;44:2048-58. [PMID: 30116873 DOI: 10.1007/s00261-018-1724-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
296 Ohkura Y, Ueno M, Udagawa H. Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. World J Surg Oncol 2019;17:125. [PMID: 31315622 DOI: 10.1186/s12957-019-1665-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
297 Zheng YZ, Zhao W, Hu Y, Ding-Lin XX, Wen J, Yang H, Liu QW, Luo KJ, Huang QY, Chen JY, Fu JH. Aggressive surgical resection does not improve survival in operable esophageal squamous cell carcinoma with N2-3 status. World J Gastroenterol 2015; 21(28): 8644-8652 [PMID: 26229406 DOI: 10.3748/wjg.v21.i28.8644] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
298 Liu S, Qiu B, Luo G, Liang Y, Zheng Y, Chen Z, Luo K, Xi M, Liu Q, Hu Y, Li Q, Fu J, Liu M, Yang H, Liu H. TNM Staging Matched-pair Comparison of Surgery After Neoadjuvant Chemoradiotherapy, Surgery Alone and Definitive Chemoradiotherapy for Thoracic Esophageal Squamous Cell Carcinoma. J Cancer 2017;8:683-90. [PMID: 28367248 DOI: 10.7150/jca.17048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
299 Ming XY, Zhang X, Cao TT, Zhang LY, Qi JL, Kam NW, Tang XM, Cui YZ, Zhang BZ, Li Y, Qin YR, Guan XY. RHCG Suppresses Tumorigenicity and Metastasis in Esophageal Squamous Cell Carcinoma via Inhibiting NF-κB Signaling and MMP1 Expression. Theranostics 2018;8:185-98. [PMID: 29290801 DOI: 10.7150/thno.21383] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
300 Boucher ANC, Ng O, Saunders JH, Acheson AG, Parsons SL. Anaemia and its effects on tumour regression grade and survival following chemotherapy in adenocarcinoma of the oesophagus. J Gastrointest Oncol 2018;9:797-805. [PMID: 30505578 DOI: 10.21037/jgo.2018.06.05] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
301 Del Calvo H, Nguyen DT, Chan EY, Chihara R, Graviss EA, Kim MP. Surgery provides improved overall survival in surgically fit octogenarians with esophageal cancer after chemoradiation therapy. J Thorac Dis 2021;13:5875-86. [PMID: 34795936 DOI: 10.21037/jtd-21-928] [Reference Citation Analysis]
302 Zheng Y, Li Y, Liu X, Zhang R, Wang Z, Sun H, Liu S. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study. J Cancer 2019;10:1097-102. [PMID: 30854116 DOI: 10.7150/jca.29353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
303 Song Q, Wu JZ, Jiang HF, Wang S, Cai SN. The Postoperative Lymphocyte to Monocyte Ratio Change Predicts Poor Clinical Outcome in Patients with Esophageal Squamous Cell Carcinoma Undergoing Curative Resection. Dis Markers 2020;2020:1451864. [PMID: 32377268 DOI: 10.1155/2020/1451864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
304 Tao CJ, Lin G, Xu YP, Mao WM. Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review. J Cancer 2015;6:1179-86. [PMID: 26516367 DOI: 10.7150/jca.12346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
305 Huang YH, Chen KC, Lin SH, Huang PM, Yang PW, Lee JM. Robotic-assisted single-incision gastric mobilization for minimally invasive oesophagectomy for oesophageal cancer: preliminary results. Eur J Cardiothorac Surg 2020;58:i65-9. [PMID: 32617584 DOI: 10.1093/ejcts/ezaa212] [Reference Citation Analysis]
306 Yang PW, Chang YH, Wong LF, Lin CC, Huang PM, Hsieh MS, Lee JM. The genetic effect and molecular function of the SOCS5 in the prognosis of esophageal squamous cell carcinoma. J Cancer 2021;12:2216-29. [PMID: 33758600 DOI: 10.7150/jca.51806] [Reference Citation Analysis]
307 Fang X, Shrestha SM, Ren LH, Shi RH. Biological and clinical implications of metastasis-associated circular RNAs in oesophageal squamous cell carcinoma. FEBS Open Bio 2021;11:2870-87. [PMID: 34510785 DOI: 10.1002/2211-5463.13297] [Reference Citation Analysis]
308 Wang G, Tang J, Zhan W, Zhang R, Zhang M, Liao D, Wang X, Wu Y, Kang T. CBX8 Suppresses Tumor Metastasis via Repressing Snail in Esophageal Squamous Cell Carcinoma. Theranostics 2017;7:3478-88. [PMID: 28912889 DOI: 10.7150/thno.20717] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
309 Zhou HY, Zheng SP, Li AL, Gao QL, Ou QY, Chen YJ, Wu ST, Lin DG, Liu SB, Huang LY, Li FS, Zhu HY, Qiao GB, Lanuti M, Yao HR, Yu YF. Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study). EClinicalMedicine 2020;24:100422. [PMID: 32637899 DOI: 10.1016/j.eclinm.2020.100422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]